Principal Investigator: A phase I study of the EGFR-TK inhibitor, OSI-774, in combination with Docetaxel and radiation in locally advanced squamous cell cancer of the head and neck (NCI #5389, CWRU 1301)
Eastern Cooperative Oncology Group young investigator award 2001
Fellowship in Hematology Oncology New England Medical Center
Medical Residency Harvard Medical School/ Mt. Auburn Hosp.
MPH Harvard School of Public Health
Education:
Master of Public Health - 1996 -
Harvard School of Public Health, Boston
Ph.D. - 1990 - Doctoral Thesis - Elastic Tissue Disorders in Thalassemia Major.
M.D. - 1986 - University of Athens Medical School.
Postdoctoral Training:
2002 - 2003 - Clinical and Research Fellow -
Divisions of Hematology-Oncology and Clinical Care Research
New England Medical Center/Tufts Medical School
2000 - 2002 - Resident, Internal Medicine - Mount Auburn Hospital/ Harvard Medical School
1996 - 2000 - Fellow, Hematology-Oncology - New England Medical Center
1998 - 2000 - Fellow, Clinical Care Research-
New England Medical Center
1992 - 1995 - Fellow, Hematology -
University of Athens Medical School, Greece.
1989 -1992 - Research Fellow,
Dept. of Hematology, Children’s Hospital -
Harvard Medical School, Boston, MA.
1987 - 1989 - Residency in Internal Medicine -
University of Athens Medical School, Greece.
Professional Societies:
1996: Massachusetts Medical Society, Member
1998: American Society of Hematology, Member
2000: American Society of Cancer Research, Associate Member
2001: American Society of Clinical Oncology, Member
Awards and Honors:
2001: “Young Investigator Award” Eastern Cooperative Oncology Group
(ECOG) Semiannual meeting, Miami FL.
1999: “Best Clinical Presentation” award (Fellows’ Competition).
60th annual meeting of the New England Cancer Society.
Providence, RI.
1992: “Malamos” Clinical Research Award.
University of Athens School of Medicine, Greece.
Conferred every two years to most promising clinical research by a young
investigator, recent graduate of the university of Athens Medical School.
Publications:
1. Germenis A, Savvides P, Dimopoulos MA, Becopoulos T, Fertakis A, Dimopoulos C. Marquers genetique dans l'hyperthrophie benigne de la prostate. La Presse Medicale 1983, 12:751 52.
2. Dimopoulos MA, Germenis A, Savvides P, Karayannis A, Fertakis A, Dimopoulos C. Marquers genetique dans le cancer papillaire de la vessie. Journal d'Urologie 1983, 89:693 94.
3. Dimopoulos MA, Germenis A, Savvides P, Karayannis A, Fertakis A, Dimopoulos C. Genetic markers in carcinoma of the prostate. European Urology 1984, 10:315 16.
4. Germanis A, Savvides P. Erythrocyte blood cells substitutes. Iatriki 1988, 53:411 14.
5. Aesopos A, Stamatelos G, Savvides P, Rombos I, Tassiopoulos, Kaklamanis F. Pseudoxanthoma elasticum and angioid streaks in two cases of b thalassaemia. Clin Rheumatol 1989, 8(4):522 27.
6. Aesopos A, Stamatelos G, Savvides P, Kavouklis E, Gabriel L. Rombos I, Karagiorga M, Kaklamanis P. Angioid streaks in homozygous b-thalassemia. Am J Ophthalmol 1989, 108(4):356 59.
7.Aessopos A, Savvides P, Stamatelos G, Rombos I, Tassiopoulos T, Karagiorga M, Kaklamanis P, Fessas P. Pseudoxanthoma elasticum-like skin lesions and angioid streaks in beta- thalassemia. Am J Hematol 1992, 41(3): 159-64.
8. Savvides P, Shalev O, John KM, Lux SE. Combined spectrin and ankyrin deficiency is common in autosomal dominant hereditary spherocytosis. Blood 1993, 82:2953-60.
9. Makrigiorgos,M., Kassis,A., Mahmood,A., Bump,E and Savvides,P.
Novel Fluorescein-Based Flow-Cytometric Method for Detection of Lipid Peroxidation. Free Radical Biology and Medicine 1997, 22(1-2): 93-100.
10. Maulik G, Kassis AI, Savvides P and Makrigiorgos GM. Fluoresceinated phosphoethanolamine for flow-cytometric measurement of lipid peroxidation. Free Radical Biology and Medicine 1998, 25(6): 645-53.
11. Savvides P, Terrin N, Erban J, Selker HP. Development and Validation of a Patient-Specific Predictive Instrument for the Need for Dose-Reduction in Chemotherapy for Breast Cancer: A Potential Decision Aid for the Use of Myeloid Growth Factors. Supportive Care in Cancer 2003, 11(5): 313-20.
Presentations - Abstracts:
1. Deficiency of band 3 in dominant hereditary spherocytosis with normal spectrin content. Lux SE, Bedrosian C, Shalev O, Morris M, Chassis J, Davies K, Savvides P, Telen M. Presented at the AAP/ASCI/AFCR meeting, Washington, DC. Clin Res 1990, 38:300A.
2. Erythrocyte membrane defects in patients with hereditary spherocytosis in Greece. Premetis V, Savvides P, Stamoulakatou A,Loukopoulos D. 1st Meeting of the European Society of Hematology. Brussels, June 1994.
3.Nephroprotective effect of Imipenem/Cilastatin in Allogeneic and MUD bone marrow transplantation. Results from a retrospective analysis. Savvides P, Relias V, Schenkein DP, Selker H, Miller KB. 1999 Annual Meeting of the American Society of Clinical Oncology. Atlanta, May 1999.
4. Predictive Instrument for the need for Dose Reductions in Chemotherapy for Patients with Breast Cancer: A Potential Decision Aid for the Use of Myeloid Growth Factors. Savvides P, Terrin N, Erban J, Selker HP. 1999 Eastern Cooperative Oncology Group Meeting. Education Program of the Breast Committee. Tampa FL, November 1999.
5. A Predictive Instrument for the need for Dose Intensity Reductions in Chemotherapy for Patients with Breast Cancer: A Potential Decision Aid for the Use of Myeloid Growth Factors. Savvides P, Terrin N, Erban J, Selker HP. 2000 Annual Meeting of the American Association for Cancer Research. San Fransisco CA, April 2000.
6.Development and Validation of a Patient-Specific Predictive Instrument for the Need for Dose-Reduction in Chemotherapy for Breast Cancer: A Potential Decision Aid for the Use of Myeloid Growth Factors. Savvides P, Terrin N, Erban J, Selker HP. 2001 Annual Meeting of the American Society of Clinical Oncology. San Fransisco CA, May 2001.
7.Development of a Cox proportional hazards (Cox-PH) model of time to first dose reduction in women undergoing breast cancer chemotherapy. Savvides P, Terrin N, Erban J, Selker HP. 24th Annual San Antonio Breast Cancer Symposium. San Antonio TX, December 2001.
8. Multivariate analysis of the factors influencing dose-selection of denileukin diftitox (ONTAK) in patients with CTCL. Foss F, Savvides P. 43rd American Society of Hematology Annual Meeting. Orlando, FL. December 2001.
Department of Medicine|
11100 Euclid Avenue| Cleveland, Ohio 44106
